GSK Belantamab Mafodotin shows to help blood cancer patients Medical Dialogues Bureau26 Aug 2019 9:15 AM ISTTwo doses of Belantamab Mafodotin helped subdue the disease in adults who had received three prior treatments for multiple myeloma, a cancer of the...
GSK pharma head flags need for speed in high-pressure drug market Medical Dialogues Bureau18 Jun 2019 2:06 PM ISTLONDON: Doing things one at a time in drug development is not a luxury that GlaxoSmithKline can afford any longer, the head of pharmaceuticals at...
FDA approves new blood cancer treatment from Pfizer Medical Dialogues Bureau22 Nov 2018 9:15 AM ISTThe U.S. Food and Drug Administration on Wednesday approved Pfizer Inc's drug to treat a form of blood cancer in newly diagnosed patients as a...
Johnson & Johnson profit beats, lifts forecast on cancer drug demand Medical Dialogues Bureau17 Oct 2018 9:10 AM ISTJohnson & Johnson reported slightly better-than-expected third quarter profit and raised its full-year forecast on Tuesday as increased demand for...
Gene therapy for rare form of blindness wins US approval Ruby Khatun Khatun21 Dec 2017 10:04 AM ISTWASHINGTON: U.S. health officials on Tuesday approved the nation's first gene therapy for an inherited disease, a treatment that improves the sight of...
Roche lymphoma drug drives high remission rate, longer survival: study Ruby Khatun Khatun12 Dec 2017 10:00 AM ISTAn experimental Roche Holding AG drug, added to standard therapy, led to a far higher rate of remission and helped patients with an advanced,...
Novartis CAR-T therapy leads to durable response in lymphoma study Ruby Khatun Khatun11 Dec 2017 10:45 AM ISTPatients with an advanced form of an aggressive blood cancer who had initially responded to Novartis' new type of gene-modifying immunotherapy...
Gilead Sciences new drug keeps 56 percent of lymphoma trial patients alive Ruby Khatun Khatun11 Dec 2017 10:30 AM ISTMore than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a...
Johnson multiple myeloma drug succeeds in first-line combination study Ruby Khatun Khatun23 Nov 2017 10:00 AM ISTJohnson and Johnson's blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or...
FDA backs Roche Gazyva in first-line follicular lymphoma Ruby Khatun Khatun20 Nov 2017 9:30 AM ISTZURICH: The U.S. Food and Drug Administration on Thursday expanded approvals for Roche's Gazyva to include previously untreated follicular lymphoma,...
Europe ready to embrace first copies of biotech cancer drugs supriya kashyap kashyap17 Feb 2017 12:25 PM ISTLondon : Treatment with two important cancer drugs is about to get much cheaper in Europe with a cut-price copy of Roche's blood cancer drug Rituxan...
